{
  "chapter": "Git Pharmacology-Drugs In Acid Peptic Disease",
  "questions": [
    {
      "q_no": 1,
      "question": "A 58-year-old male with a history of chronic kidney disease presents with worsening epigastric pain and frequent heartburn. Given his renal impairment, which class of medications for Peptic ulcer disease should be avoided, and which specific agent would provide the most optimal relief without exacerbating his comorbid conditions as well as for long-term use?",
      "options": {
        "A": "Avoid proton pump inhibitors; use ranitidine.",
        "B": "Avoid antacids containing magnesium; use omeprazole.",
        "C": "Avoid H2 receptor antagonists; use sucralfate.",
        "D": "Avoid proton pump inhibitors; use calcium carbonate."
      },
      "correct_answer": "B",
      "explanation": "Correct Answer : B) Avoid antacids containing magnesium; use omeprazole. Explanation: Antacids containing magnesium (e.g. Magnesium hydroxide and Magaldrate) should be avoided in patients with renal impairment because they can lead to hypermagnesemia. Omeprazole, a proton pump inhibitor, is generally safe for use in patients with chronic kidney disease and is effective for treating acid peptic disease. This is the most appropriate option. Avoid proton pump inhibitors; use ranitidine ( Option A) : Proton pump inhibitors (PPIs) are the DOC for acid peptic disease and are not contraindicated in renal impairment. Ranitidine, an H2 receptor antagonist, was commonly used for acid-related conditions but has been withdrawn from the market due to carcinogenic risk. Avoid H2 receptor antagonists; use sucralfate ( Option C): H2 receptor antagonists can generally be used in patients with renal impairment. Sucralfate is a mucosal protectant that can provide symptomatic relief by coating ulcers and protecting them from stomach acid. However, it is less effective than PPIs for acid suppression. Avoid proton pump inhibitors; use calcium carbonate ( Option D): While calcium carbonate (a type of antacid) can provide symptomatic relief, it may lead to hypercalcemia and potential renal complications. On long term use, Calcium ions diffuse into the gastric mucosa and increase HCl production directly by parietal cells as well as by releasing gastrin. Acid rebound occurs. Avoiding PPIs is unnecessary in renal impairment. Gastric acid secretion inhibitors: M1 blocker-Pirenzepine, Telenzepine K-CAB blocker- Vonoprazan",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 2,
      "question": "A 30-year-old primigravida presents with complaints of recurrent heartburn and epigastric discomfort. She has a history of closed-angle glaucoma, which is currently well-managed with medication. Considering her medical history, which combination of acid-suppressant drugs should be avoided?",
      "options": {
        "A": "PPIs only",
        "B": "H2 blockers only",
        "C": "Anticholinergics only",
        "D": "Anticholinergics and Prostaglandin analogues"
      },
      "correct_answer": "D",
      "explanation": "Correct answer: D) Anticholinergics and Prostaglandin analogues Explanation: Anticholinergics can cause pupillary dilation, leading to an increase in intraocular pressure, which can precipitate an acute angle closure glaucoma attack. Prostaglandin analogues can cause uterine contractions and are contraindicated in pregnancy due to the risk of abortion or premature labor. Classification of acid suppressant drugs with mechanism of action: Acid Suppressant Drugs Mechanism of Action Proton Pump Inhibitors (PPIs) (Option A) Irreversibly inhibit the H+/K+ ATPase pump in the gastric parietal cells, leading to sustained suppression of gastric acid secretion. H2 Blockers (Option B) Competitively antagonizes histamine H2 receptors on the surface of gastric parietal cells, thereby diminishing the stimulatory effect of histamine on the production of gastric acid. Prostaglandin Analogues Stimulate prostaglandin E2 receptors on gastric epithelial cells, promoting the secretion of mucus and bicarbonate while inhibiting gastric acid secretion. Anticholinergics (Option C) Act as competitive antagonists at M3 muscarinic receptors in the stomach, inhibiting the stimulatory effects of acetylcholine on gastric acid secretion and motility. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 697",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 3,
      "question": "A 42-year-old man presents with heartburn and epigastric pain, diagnosed with peptic ulcer disease. The doctor opts for a PPI, choosing between Ilaprazole, Lansoprazole, Rabeprazole and Omeprazole. Which of these medications requires the lowest dosage to achieve equivalent therapeutic effects?",
      "options": {
        "A": "Ilaprazole",
        "B": "Lansoprazole",
        "C": "Rabeprazole",
        "D": "Omeprazole"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer : A) Ilaprazole Explanation: Potency of PPIs - Dex Rabeprazole > Ilaprazole > Lansoprazole > Rabeprazole > Omeprazole > Pantoprazole All PPIs have equal efficacy. Route of Administration: Oral: All PPIs Injectable: IV/IM (Pantoprazole, Es-omeprazole, Rabeprazole) Properties: Acid production reduction persists for 2 to 4 days even after stopping the drug and resumes later. Duration of action is typically 2 to 4 days. Omeprazole is the fastest acting PPI. PPIs are acid labile; Enteric coating can protect from acid degradation. They should be taken on empty stomach when only ~I0% of proton pumps are active, followed 1 hour later by a meal to activate the H+/K+/ATPase at a time when plasma concentration of the PPI is maximal. Metabolism and Interactions: All PPIs are metabolised by the CYP2C19 enzyme. Omeprazole is the maximum CYP inhibitor. Rabeprazole has the lowest CYP inhibition, followed by Pantoprazole. Omeprazole should never be given with Clopidogrel due to potential interactions. Omeprazole inhibits the enzyme CYP2C19, thus preventing the conversion of Clopidogrel to its active metabolite. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 700",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 4,
      "question": "A 68-year-old female patient with a history of myocardial infarction is currently on dual antiplatelet therapy, including clopidogrel. She visited a government hospital where an intern prescribed her omeprazole to be taken in the morning, not knowing that omeprazole is contraindicated with clopidogrel. Which Cytochrome P450 enzyme is implicated with respect to the reduced effectiveness of clopidogrel when taking omeprazole?",
      "options": {
        "A": "CYP2C9",
        "B": "CYP2C19",
        "C": "CYP3A4",
        "D": "CYP2D6"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer : B) CYP2C19 Explanation - Omeprazole inhibits the enzyme CYP2C19, which is crucial for converting clopidogrel into its active metabolite. This interaction reduces the effectiveness of clopidogrel, potentially decreasing its ability to prevent blood clots in patients who are at risk, such as those with a history of myocardial infarction. If a patient requires both clopidogrel and a PPI, it is recommended to use pantoprazole or rabeprazole to reduce the risk of interaction. Omeprazole reduces the metabolism of antidepressants and antipsychotics, increasing the chances of toxicity. Alongside, Omeprazole also blocks the activation of Tamoxifen. Omeprazole also inhibits other CYP enzymes like CYP2C9, CYP2D6 & CYP3A4. However, these enzymes are not involved in metabolic activation of Clopidogrel. (Option A, C and D ruled out) Reference: Pubmed- Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 912",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 5,
      "question": "Which of the following is incorrect with respect to the adverse effects of chronic use of proton pump inhibitors (PPI)? atrophic gastritis.",
      "options": {
        "A": "Use of PPI is associated with reduced absorption of B12, Mg, and Iron.",
        "B": "Long-term use of PPI is associated with an increased risk of bone fractures.",
        "C": "Increased risk of pseudomembranous enterocolitis is associated with long-term use of PPI.",
        "D": "Reduced serum gastrin levels can occur due to long-term use of PPI, causing ECL hyperplasia and"
      },
      "correct_answer": "D",
      "explanation": "ECL hyperplasia and atrophic gastritis. Correct answer: D) Reduced serum gastrin levels can occur due to long-term use of PPI, causing ECL hyperplasia and atrophic gastritis. Explanation: Chronic use of PPIs can lead to hypergastrinemia, which can further result in: ECL hyperplasia Fundic gland polyposis Atrophic gastritis Hypergastrinemia is detected by measuring serum gastrin levels. This condition may predispose individuals to rebound hypersecretion of gastric acid upon discontinuation of therapy and may also promote the growth of gastrointestinal tumours. Other side effects of PPI use include: Gastrointestinal upset (nausea, constipation, diarrhoea). Increased microbial growth leads to a higher risk of hospital-acquired pneumonia, community-acquired Clostridium difficile infection, spontaneous bacterial peritonitis and pseudomembranous enterocolitis (Option C ruled out) . Increased risk of bone fractures due to hypocalcemia (reduced absorption of calcium) (Option B ruled out) . Reference: Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 912",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 6,
      "question": "A 38-year-old male with a history of frequent episodes of acidity was prescribed an H2 receptor antagonist. During a follow-up visit, he reports loss of libido and erectile dysfunction. Laboratory tests reveal elevated prolactin levels. Which of the following is the most likely cause of these symptoms?",
      "options": {
        "A": "Ranitidine",
        "B": "Famotidine",
        "C": "Nizatidine",
        "D": "Cimetidine"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Cimetidine Explanation: Cimetidine, an H2 receptor antagonist, can cause anti-androgenic effects, leading to loss of libido and erectile dysfunction. It can also increase prolactin levels, contributing to these symptoms. These side effects are more commonly associated with cimetidine than with other H2 receptor antagonists like Famotidine. Side effects associated with H2 Blockers: Gastrointestinal : Nausea, vomiting, diarrhoea and constipation. Neurological : Headache and dizziness. Endocrine and Reproductive : Gynecomastia, erectile dysfunction, loss of libido and elevated prolactin levels. Hematologic : Thrombocytopenia and agranulocytosis. Hepatic : Elevated Liver Enzymes and hepatotoxicity. Renal : Interstitial Nephritis Drugs causing gynecomastia: D: Dopamine antagonists (e.g., antipsychotics like risperidone, and metoclopramide) I: Isoniazid (antitubercular drug) S: Spironolactone (a potassium-sparing diuretic) C: Cimetidine (an H2 receptor antagonist) O: Oestrogens (including some medications like hormone replacement therapy) Reference: Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 913",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 7,
      "question": "A 32-year-old woman seeks advice on medication to prevent gastric ulcers. She has a history of rheumatoid arthritis and has been on long-term NSAID therapy. Her medical history reveals no contraindications to the use of prostaglandin analogues. The physician considers prescribing Misoprostol for ulcer prevention. Which of the following is the most appropriate counseling point regarding the use of Misoprostol in this patient? contraception.",
      "options": {
        "A": "Misoprostol should be taken on an empty stomach to enhance absorption.",
        "B": "Misoprostol is contraindicated in women of childbearing potential unless they are using effective",
        "C": "Misoprostol can be safely used in patients with a history of allergy to prostaglandins.",
        "D": "Misoprostol works by inhibiting the H2 receptors in the stomach lining to reduce acid secretion."
      },
      "correct_answer": "B",
      "explanation": "are using effective contraception. Correct Answer: B) Misoprostol is contraindicated in women of childbearing potential unless they are using effective contraception. Explanation: Misoprostol is contraindicated for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with the use of the NSAID. It is also completely contraindicated during pregnancy because it can increase uterine contractility and abort a pregnancy. Misoprostol is a longer-acting synthetic PGE1 derivative that acts on EP receptors (EP2, EP3, and EP4) to increase mucin and bicarbonate production and decrease HCl production. (Option D) It has a shorter duration of action. Taking misoprostol with food may potentially reduce the incidence of systemic side effects by lowering the early high peak plasma concentrations of misoprostol acid. (Option A) Recommended dose: 200 µg four times daily. Primary indication: prevention and treatment of NSAID-associated gastric ulcer and bleeding. But PPI is the DOC. Adverse effects seen with misoprostol use: Diarrhea, abdominal cramps, uterine bleeding, abortion. Contraindicated in Pregnancy, Inflammatory bowel disease (IBD), previous episodes of allergy to prostaglandins (Option C). Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page. 702 Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 8,
      "question": "Which of the following statements is true regarding the use of Bismuth compounds in ulcer treatment?",
      "options": {
        "A": "They inhibit the proton pump in gastric parietal cells.",
        "B": "They form a protective layer over the ulcer base, shielding it from acid and pepsin.",
        "C": "They primarily act as antacids.",
        "D": "They are H2 receptor antagonists."
      },
      "correct_answer": "B",
      "explanation": "pepsin. Correct answer: B)They form a protective layer over the ulcer base, shielding it from acid and pepsin. mucus glycoprotein, forming a protective layer over the ulcer base. Ulcer Protective Agents: Bismuth Sucralfate Properties Water-soluble, but precipitates when pH <5. Basic aluminium salt of sulfated sucrose. Polymerises at pH <4, forming a sticky gel-like consistency. Mechanism of Action Increases production of gastric mucosal prostaglandin E, mucus, and bicarbonate. Precipitate mucus glycoproteins and coat the ulcer base. Detach and inhibit Helicobacter pylori directly. Precipitates surface proteins at the ulcer base, creating a physical barrier against acid, pepsin, and bile. Does not neutralise acid but delays gastric emptying. Potentially augments gastric mucosal prostaglandin synthesis for additional protection. Dosage and Administration 120 mg taken half an hour before the three major meals and at bedtime for 4-8 weeks. 1 gram taken on an empty stomach one hour before the three major meals and at bedtime for 4-8 weeks. Side Effects Diarrhoea Headachy Dizziness Blackening of the tongue, dentures, and stools. Constipation Hypophosphatemia Dry mouth Nausea Indications Gastritis and non-ulcer dyspepsia associated with H. pylori. Occasionally used as part of a triple-drug regimen. Bile reflux, gastritis and prophylaxis of stress ulcers. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 704-705.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 9,
      "question": "Which of the following clinical features is characteristic of Milk-Alkali Syndrome?",
      "options": {
        "A": "Hyperkalemia",
        "B": "Metabolic acidosis",
        "C": "Hypercalcemia",
        "D": "Hypophosphatemia"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Hypercalcemia Explanation: Milk-Alkali Syndrome is a condition caused by excessive intake of calcium and absorbable alkali , typically from calcium supplements and antacids (e.g., calcium carbonate). It leads to a classic triad: Hypercalcemia Metabolic alkalosis Renal insufficiency The elevated calcium levels are central to the syndrome and cause various clinical symptoms including fatigue, nausea, polyuria, confusion, and even arrhythmias. Milk-Alkali Syndrome Feature Details Cause Excess intake of calcium + absorbable alkali (e.g., calcium carbonate) Key Lab Findings Hypercalcemia, Metabolic alkalosis, Hypophosphatemia, Low PTH Symptoms Nausea, vomiting, weakness, mental status changes, polyuria, kidney injury Mechanism Calcium-induced diuresis → volume depletion → increased bicarbonate reabsorption Management Discontinue offending agents, IV hydration, loop diuretics if needed Hyperkalemia (Option A): Incorrect – Patients typically have hypokalemia due to renal losses. Metabolic acidosis (Option B): Incorrect – Metabolic alkalosis is characteristic, not acidosis. Hypophosphatemia (Option D): Incorrect – While often present, it's not the most characteristic feature; hypercalcemia is the hallmark . Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page703",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 10,
      "question": "A 68 y/o female presents to the emergency department with severe abdominal pain, bloating and difficulty breathing. She has a H/O CKD and GERD. The patient admits to using sodium bicarbonate antacids frequently to manage her GERD symptoms. On examination, her abdomen is distended and she exhibits signs of peritonitis. An abdominal X-ray reveals free air under the diaphragm. Which of the following is the most likely cause of the patient's symptoms?",
      "options": {
        "A": "Hyperkalemia from excessive sodium bicarbonate use.",
        "B": "Excessive gas production from sodium bicarbonate neutralising stomach acid.",
        "C": "Hypocalcemia-induced muscle spasms causing bowel rupture.",
        "D": "Hypermagnesemia from concomitant use of magnesium-containing antacids."
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) Excessive gas production from sodium bicarbonate neutralising stomach acid. the patient. Sodium bicarbonate antacids neutralise stomach acid, producing CO2 gas as a byproduct. Excessive gas can lead to significant gastric and intestinal distension in patients who use these antacids frequently or in large amounts. This increased intraluminal pressure can cause discomfort, and bloating, and, in severe cases, lead to perforation of the bowel. This is particularly risky in individuals with predisposing conditions like CKD, where the handling of excess sodium and bicarbonate might be compromised, exacerbating the problem. Hyperkalemia is not caused by sodium bicarbonate use ( Option A ruled out). Hypocalcemia - induced muscle spasms causing bowel rupture (Option C) is a rare but severe complication associated with hypoparathyroidism and is not associated with Sodium bicarbonate use. Hypermagnesemia from concomitant use of magnesium-containing antacids (Option D) is not related to sodium bicarbonate but to magnesium-containing antacids. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 703 Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 1079",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 11,
      "question": "A 25 y/o female, a competitive gymnast presents with complaints of heartburn. She has a history of regular consumption of dairy-based calcium supplements for the past 5 years to help with her athletic lifestyle. She insists the doctor prescribe her calcium-based antacids. The doctor suggests against it and explains to her the reason. Why did the doctor suggest against it?",
      "options": {
        "A": "Risk of developing diarrhea",
        "B": "Risk of developing osteoporosis",
        "C": "Risk of developing milk-alkali syndrome",
        "D": "Risk of developing hypertension and edema"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Risk of developing milk-alkali syndrome Explanation: The patient is already on dairy-based calcium supplements for a prolonged period. Adding calcium-based antacids would put her at risk of developing Milk Alkali syndrome. Milk Alkali Syndrome is a recognized risk with excessive intake of dairy and absorbable alkali (Like CaCO3- a calcium-based antacid), leading to hypercalcemia, alkalosis, and renal insufficiency. Symptoms can include nausea, vomiting, confusion, and in severe cases, kidney failure. Side effects of other antacids Calcium-based antacids typically cause constipation rather than diarrhea. Diarrhea is more commonly associated with magnesium-based antacids. (Option A ruled out) Calcium is essential for bone health, and calcium-based antacids could actually help prevent osteoporosis by supplementing calcium. Osteoporosis is usually a side effect associated with aluminum-based antacids. (Option B ruled out) Calcium-based antacids are not typically associated with causing hypertension or edema. These conditions are more commonly related to sodium-based antacids. Hence should not be given to patients with CHF. ( Option D ruled out) Reference: Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 1079 Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 703",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 12,
      "question": "A 72-year-old woman with a history of CHF (congestive heart failure) presents to the clinic complaining of heartburn, chest pain, and regurgitation of food after meals for the past week. Her CHF symptoms are currently well-controlled with medication. On examination, there is no evidence of angina pectoris. Which medication would be MOST APPROPRIATE for this patient’s symptoms?",
      "options": {
        "A": "Magaldrate",
        "B": "Sodium Bicarbonate",
        "C": "Aspirin",
        "D": "Metoprolol"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) Magaldrate Explanation: The patient’s symptoms of heartburn, chest pain, and regurgitation of food after meals are suggestive of GERD. Magaldrate is a nonsystemic antacid and is a combination of two antacids: magnesium hydroxide and aluminum hydroxide and can be safely used in patients with heart disease. Magnesium hydroxide reacts quickly with stomach acid to neutralize it, providing rapid relief from heartburn. However, it causes diarrhea as a side effect. Aluminum hydroxide works slower but provides longer-lasting relief. It also coats the esophagus, protecting it from further irritation by stomach acid. However, it causes constipation as a side effect. Hence, Magaldrate is a fixed combination of the two and works by counteracting each other’s adverse effects and hence giving optimum results. Sodium Bicarbonate (Option B) is a high sodium antacid, which can worsen fluid retention in CHF patients causing hypertension and edema. It is usually contraindicated in patients with heart disease. Aspirin (NSAID) (Option C) can worsen heartburn symptoms and should be avoided. Metoprolol (Option D) is a beta-blocker used to treat high blood pressure and angina pectoris, but it is not typically used for GERD. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 703 Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 1079",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 13,
      "question": "A 5y/o girl is brought to the emergency department by her parents with complaints of persistent vomiting, confusion, and lethargy. The parents mentioned that she had a viral illness two weeks prior, during which she was given a combination of medications to alleviate her symptoms. On examination, the child is found to be drowsy, with signs of hepatomegaly. Laboratory tests reveal elevated liver enzymes and ammonia levels. Which of the following medications is most likely associated with the child's current presentation?",
      "options": {
        "A": "Paracetamol",
        "B": "Amoxicillin",
        "C": "Bismuth subsalicylate",
        "D": "Ranitidine"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Bismuth Subsalicylate Explanation: The patient’s symptoms, clinical presentation, and lab values suggest she has Reye’s Syndrome. Reye's syndrome is a rare but serious condition that causes swelling in the liver and brain. It most commonly affects children and teenagers recovering from a viral infection, such as influenza or chickenpox. The use of salicylates during such viral infections has been strongly associated with the development of Reye's syndrome. Bismuth subsalicylate, found in some over-the-counter medications for stomach upset (such as Pepto-Bismol), contains salicylate, which can lead to Reye's syndrome when used in children recovering from viral infections. Other commonly used salicylates include: Aspirin: an NSAID Methyl Salicylate : found in topical relief creams and ointments Other side effects of Bismuth include: Black tongue and black faeces - when bismuth salicylate comes in contact with sulfur compounds in mouth and GIT, it forms Bismuth sulfide which is a black compound. Bone : Osteoporosis Paracetamol ( Option A) is widely used as an analgesic and antipyretic. While an overdose of it can lead to acute liver failure, it is not associated with Reye's syndrome. Amoxicillin ( Option B) is an antibiotic commonly used for URIs and is not associated with Reye's syndrome. Ranitidine ( Option D) is an H2 receptor antagonist used to reduce stomach acid production. It is not linked to Reye's syndrome. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 703 Goodman and Gilman's- The Pharmacological Basis of Therapeutics, 14th Edition, Page 1096",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 14,
      "question": "A 45-year-old male patient presents with symptoms of peptic ulcer disease and is diagnosed with H. pylori infection. He is allergic to penicillin. As part of his initial treatment, you decide to start him on triple therapy for H. pylori eradication. Which of the following drugs are used in Triple therapy in this patient?",
      "options": {
        "A": "PPI + Clarithromycin + Metronidazole for 14 days",
        "B": "PPI + Clarithromycin + Amoxicillin for 14 days",
        "C": "PPI + Levofloxacin + Clarithromycin for 14 days",
        "D": "PPI + Clarithromycin + Metronidazole for 7 days"
      },
      "correct_answer": "A",
      "explanation": "allergic to penicillin so Amoxicillin is avoided, hence he has to be started on PPI + Clarithromycin + Metronidazole for 14 days. Antibiotics used against H. Pylori: Generation Clarithromycin Amoxicillin Metronidazole 1st generation Tetracycline Levofloxacine 2nd generation Rifabutin Furazolidone 3rd generation Guidelines for treatment of H.Pylori: ≥ 2 combinations of antibiotics Give PPI> H2 blocker Give for >10-14 days Anti-H.pylori regimens: Drugs used No. of days: Triple therapy: PCA (first line therapy used) PPI + Clarithromycin + Amoxicillin (Option B) BD for 14 days Triple therapy: PCM (in case of penicillin allergy or resistance) PPI + Clarithromycin + Metronidazole BD for 14 days Levofloxacin-based triple therapy: PPI + Levofloxacin + Clarithromycin (PAL) (Option C) BD for 14 days PPI + Tetracycline + Amoxicillin for 14 days (Option D) are not used in combination, instead PPI + Amoxicillin followed by PPI + Metronidazole + Levofloxacine for 14 days (PA © PML) is used as a new concomitant therapy. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 705",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 15,
      "question": "Which of the following is the most preferred treatment regimen for H pylori in India?",
      "options": {
        "A": "Triple therapy",
        "B": "Quadruple therapy",
        "C": "Sequential therapy",
        "D": "Hybrid therapy"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) Quadruple therapy Explanation: Quadruple therapy (tetracycline, metronidazole, bismuth, PPI) is effective against metronidazole resistance with a success rate of 90%+ for 10-14 days in India. Due to the risk of development of Clarithromycin resistance in India. Anti-H.pylori regimens: Drugs used No. of days: Triple therapy: PCM (in case of penicillin allergy or resistance) PPI + Clarithromycin + Metronidazole BD for 14 days Triple therapy: PCA PPI + Clarithromycin + Amoxicillin BD for 14 days Quadruple therapy (In clarithromycin resistance) PPI + Bismuth salts + Metronidazole + Tetracycline BD for 14 days Sequential therapy PPI + Amoxicillin (for 7 days) © PPI + Clarithromycin + Metronidazole (for 7 days) BD For 14 days Hybrid therapy PPI + Amoxicillin (for 7 days) © PPI + Clarithromycin + Amoxicillin + Metronidazole (for 7 days) BD For 14 days Reference: H pylori infection different regimens",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    },
    {
      "q_no": 16,
      "question": "A 50-year-old patient with a history of gastroesophageal reflux disease (GERD) reports persistent symptoms despite lifestyle modifications and dietary changes. The physician decides to add alginic acid to the patient's treatment regimen. What is the mechanism of action of alginic acid in the treatment of GERD?",
      "options": {
        "A": "Makes a neutral covering over HCL",
        "B": "Bursts bubbles in the gastrointestinal tract",
        "C": "Increases prostaglandin synthesis",
        "D": "Polymerizes with proteins to form a protective covering"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) Makes a neutral covering over HCL Explanation: This patient with a history of GERD has failed lifestyle modifications and dietary changes, so the physician decides to prescribe Alginic acid. Mechanism of action of Alginic acid in GERD: Alginates treat GERD by forming a mechanical barrier. They create a gel in the presence of gastric acid. This gel forms a raft that localizes to the acid pocket in the proximal stomach. This prevents the acid from getting displaced to the esophagus Hence helping patients with symptoms of GERD Bursts bubbles in the gastrointestinal tract (Option B): This is the mechanism of action of surfactant-like molecules e.g; Simethicone and dimethicone Increases prostaglandin synthesis (Option C): This is the mechanism of action of Bismuth salts. Polymerizes with proteins to form a protective covering (Option D): This is the mechanism of action of Sucralfate which is ulcer protective. Reference: Essentials of Medical Pharmacology- K.D Tripathi, 8th Edition, Page 708.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Git Pharmacology-Drugs In Acid Peptic Disease"
    }
  ]
}
